my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
Powered with strategic vision and financial vigor, Clal Biotechnology Industries (CBI) Ltd is one of the largest biotechnology investment entities in Israel. CBI targets promising companies with innovative bio-pharma technologies and transforms them into thriving, productive businesses.
Backed by Clal Industries and Investments, one of Israel's largest investment companies (owned by IDB group), and Teva Pharmaceutical Industries, the world's largest manufacturer of generic drugs, CBI successfully leverages its unique investment model of large-scale, long-term financial and managerial commitment to yield significant results and valued creation.
Clal Biotechnology Industries portfolio includes D-Pharm, Mediwound, Cure Tech, Andromeda, NST, Polyheal, Compugen, and BioCancell.
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
Clal Biotechnology Industries Ltd. announced recently that Andromeda Biotech Ltd., a wholly owned subsidiary of CBI, signed a Term Sheet with Teva to develop and commercialize DiaPep277, an innovative and advanced drug for the treatment of type 1 diabetes. According to the Term Sheet, Teva ... more
Clal Biotechnology Industries Ltd.
Powered with strategic vision and financial vigor, Clal Biotechnology Industries (CBI) Ltd is one of the largest biotechnology investment entities in Israel. CBI targets promising companies with innovative bio-pharma technologies and transforms them into thriving, productive businesses. B ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
